Get started

Coronavirus (COVID-19)

EURJPY - short conceptThe third test of 3 using different pairs. GBP, Euro and US Dollar. Not a trade to copy. Just testing live hence the posts. Have a good weekend. Disclaimer This idea does not constitute as financial advice. It is for educational purposes only, our principle trader has over 20 years’ experience in stocks, ETF’s, and Forex. Hence each trade setup might have different hold times, entry or exit conditions, and will vary from the post/idea shared here. You can use the information from this post to make your own trading plan for the instrument discussed. Trading carries a risk; a high percentage of retail traders lose money. Please keep this in mind when entering any trade. Stay safe.
Short
by Mayfair_Ventures
4
USDCAD 4th leg up and 5th leg downPlaying with some ideas, not a trade to copy - testing key levels as part of a bigger picture. Hence up to then drop down. Disclaimer This idea does not constitute as financial advice. It is for educational purposes only, our principle trader has over 20 years’ experience in stocks, ETF’s, and Forex. Hence each trade setup might have different hold times, entry or exit conditions, and will vary from the post/idea shared here. You can use the information from this post to make your own trading plan for the instrument discussed. Trading carries a risk; a high percentage of retail traders lose money. Please keep this in mind when entering any trade. Stay safe.
Long
by Mayfair_Ventures
Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores. The company generates a majority of its revenue from its retail segment. The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19. www.benzinga.com twitter.com
I
by AlenCiken
It's cold in the US and EU 🥶! 1 year covid crash anniversary.The market prices info in a few days or weeks before it happens (not surprises obviously - only politicians trade those see Nancy Pelosi and Tesla for reference, as well as Hilary Clinton making 10 million percent or something on cattle futures making her the greatest trader of all time). If there is no advantage to predicting things when they are being talked about by decision makers, 10 days before they are announced, we have to predict it even earlier! Before the clueless decision makers even talk about it. We speculate on what speculators are going to speculate in the future. So, obviously this MAY happen. Last time there was a covid surge everything dropped to the ground 📉. And so I'm not sure how viruses work, well no one knows honestly, lots of ignorant journalists THINK they do but they know the least of them all. But what I saw is that states and countries in the north or far south (Argentina etc) generally had more deaths than those closer to the equator. What is happening is that since the Biden inauguration - just stating a fact, not speculating on why this is the case chill - the US & EU have relaxed their covid measures. And it is getting so cold, all of a sudden, it's hard for bodies to adapt, plus colder places have more deaths. And funny thing is the states that took less restrictive measures, and who for now have less deaths than surrounding states with economic shutdown, are located in areas that are going to get cold 🌨️🌨️🌨️. So what may happen is this: 1- The cold might lead to a spike in deaths 2- Oklahoma, Texas, Arkansas, and more, will get hit hard, and people that "take covid seriously" and paranoid people will tell them "told you so" and push for an economic shutdown, Biden has already signed dozens of executive orders so he might sign a few others what difference does it make at that point? 3- France that said "ok for now we are not restricting your liberties more, restaurants might re-open" will now say "hey it's getting worse so let's do like we did last year", the UK that already got hit hard with "their" variant (less severe BUT more contagious) will get hit even harder and so it will go into complete panic mode, spread fear to Europe and the US, lots of decisions will be taken in hindsight AFTER the worse is over (which will confirm in their eyes the measures are efficient 🤦‍♂️) 4- Markets will crash 5- Typical confirmation bias & anchoring bias & neglect of probability & oversimplification tendency & all the trading bias: If clueless politicians keep taking hindsight decisions AFTER cases & death waves it will always look like it was efficient and stopped the spread, good luck to the 150+ IQ top scientists explaining them that, way too subtle for the average voter to understand, so you already know this will be the dogma and become a recurring thing. Since I mentioned biases, this is the list 😀: Taken from here: www.magellangroup.com.au Good article I'm already short Bitcoin, and I'm getting ready to exit my Tech100 long if things go south.
TVC:DJIShort
by MrRenev
2
NFLX better get your popcorn Time to netflix and chillout or time to breakout... I am expecting a breakout here.. Consolidating for a few days now after filling out this pennant, sitting above the 200MA indicating it is still holding positive momentum and bullish divergence on the MACDs. I will be looking at this to break above the trend line and load calls upon price action, or you can apply an area of value trade and buy in the ellipse and set stop losses at last support. Popcorn is almost ready, will you be!?
NASDAQ:NFLXLong
by Verum0
5
OCGN - how to play the COVAXIN news !OCGN: What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken – double-check me on it – except AstraZeneca all of them need cooling. The vaccine of Ocugen is in cooperation with Bharat Biotech. the vaccine is supposed to be stronger against different strains of covid that are emerging …. The reason for all the noise is in the fine print -they closed a damn good deal on the sales in the U.S – they will receive 45% of profits with no upfront payment (someone was drunk when he agreed to that deal LOL)… so price target given by Roth Capital is 8$ -don’t agree – I think in the next year if all goes well this stock is above 15$ if we factor in the “meme” market going on could be much more and much faster but let's stay conservative. Ok lets talk shop – technical: POC (point of control) is not good – 3,18 but I am certain it will rise in the upcoming week – remember POC is like a “magnet” it will attract the price to it for obvious reason. Volume: average volume is 63M, last 2 days trading above 100M. 50% line of retracement is 3.95 (round it up to the 4$ area – its always areas not specific numbers ) which means we will need to see the golden number getting touched sooner or later (again consider “meme” market conditions are extremely abnormal) 4.5$ -6$ needs to be retested – there needs to be a retracement to that area with some sideways trend before we can say let’s see 8$ - in normal market conditions…. Notice on the chart the yellow square showing ling upper wicks meaning buying power got very weak – matches the volume orders on the left (the colors are somewhat faded meaning it needs accumulation), reversal signal. The red box in the lower part of the chart is the forbidden zone – it is the other side of the POC and the stock flew through that price too quick so if we see a pullback to the POC line we may see a sell-off to that area- don’t believe this will happen so soon as sentiment is very high Bottom line – I think we need to see some pull back the upcoming days before the stock goes higher to the next level of 7$-usually happens after a 2-3 days rally and once that is done we can target 7$+. Please keep in mind we are trading on a very speculative market and everything is highly inflated along with 1.9T $ coming and meme trend this is a very risky market and using my analysis on it can mean shit because it is NOT BEHAVING like it should at all !! FDGT will wait for a pullback before entering as the trend doesn’t look healthy This is not a recommendation of any sort Trader safe and be safe – we are the traders union and we trade by our own rules!
NASDAQ:OCGNLong
by FDGT_academy
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US. COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients. COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape. today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market . B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits. In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program. H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market. Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements. Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday. Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
NASDAQ:OCGN
by AlenCiken
4
Lexaria Provides Guidance on Upcoming R&DLexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The shares of common stock and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 274,285 shares of common stock and/or warrants to purchase up to 274,285 shares of common stock. finance.yahoo.com Lexaria Provides Guidance on Upcoming R&D Lexaria recently closed an oversubscribed financing of US$11 million that has greatly enhanced the Company's ability to conduct applied R&D designed to evidence effectiveness of its patented DehydraTECHTM drug delivery technology across multiple classes of bioactive substances or drugs. In the weeks to come, Lexaria expects to announce many new studies designed to provide initial evidence expected to support further study and commercial exploitation. All studies referenced within this press release are fully funded from existing Company resources. finance.yahoo.com
NASDAQ:LEXX
by AlenCiken
TYME Granted U.S. Patent Claims Treat COVID-19 InfectionsTYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19. Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19. TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication. finance.yahoo.com
T
by AlenCiken
1
Potential Development of an Oral COVID-19l VaccineAeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19. - Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement. to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine. Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19. A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial. finance.yahoo.com Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
A
by AlenCiken
Last Boarding CallAs the vaccines roll out and the world over comes the pandemic, travel will be popular among many that have been unable to for the past year. While still heavily oversold (75% below the all time high in 2018) flight centre remains in a good position to bounce back. Currently in a rising wedge, price is situated on support and is likely to take off. AWA's Travel Survey (2020) 69% of Australians hope to travel within the first six months of restrictions being lifted 50% are keen to travel for two weeks or more on their next holiday 74% said they would be comfortable spending just as much on their next holiday as they did pre COVID-19
ASX:FLTLong
by BreadCharts
3
DOW JONES INDUSTRIAL- ELEVATOR DOWN 11%DOW JONES INDUSTRIAL AVERAGE INDEX 1Hour Timeframe Short term idea: SHORTING Hello there and welcome! This one will be a quicky: -RSI: We can observe, RSI making lower lows as well as lower highs. The price -Volume: Volume is decent, but declining. It is weaker than the days before. Might turn to a bearish trend, when it first lowers and then rises while dropping to the next support zones, at what point we want to see high volume again, to determine a (temporary bottom). -Fibonacci Tool: The Index is at the 50% retracement exactly. While we dropped down from the all-time high, this is the retracement. In this retracement, we are currently back up 50%, which is an absolutely normal counter-move of a big bearish drop. In most cases, the bear trend continues. I would not give too much about the fib-levels, though many people using it, there might be some information about market behavior. -As you can see, the market tried to push through the 50% retracement level 4 TIMES. This is the fourth time, and each attempt became weaker and weaker... Expectations: I expect a decline to 20800 in the coming days! From that point, we will manage our trades again and rethink! Have a nice day, your german-quality-trader
TVC:DJIShort
by GER-Quality-Trades
2
GBPTHB Long term.Hi everyone, looking at GBPTHB, we may see that GBP formed nice candle patter to the upside, also it's at 16 years low from where we should see a pullback at least to 50 fib. As brexit, covid drives markets, loots of people will seek holidays in warm countries once allowed, and as Thailand is beloved by Brits, we may see a skyrocket in the price of thb. This information is not a recommendation to buy or sell. It is to be used for educational purposes only. "A is for my attitude working through the patience Money comes and goes so the M is for motivation Gotta stay consistent, the P is to persevere..."
Long
by Coder775
1